Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 44370 in Healthy Male Volunteers
NCT02215031Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2008
- Primary completion
- Nov 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial in migraine comparing BI 44370 with Placebo (2 arms). Primary endpoints: Number of patients with clinically significant findings in vital signs up to 16 days, Number of patients with clinically significant findings in 12-lead electrocardiogram (ECG) up to 16 days and 3 more. Started Sep 2008; status: completed.
02
Drugs
BI 44370
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02215031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215031.